What this Trial Is About

Researchers are investigating treatment options for patients with locally advanced esophageal squamous cell carcinoma (ESCC) that cannot be surgically removed. This phase II trial evaluates three different conversion therapy approaches, including combining immunotherapy with chemoradiotherapy, to improve outcomes such as complete tumor removal (R0 resection), treatment safety, and survival rates. The study focuses on patients with borderline unresectable ESCC, aiming to provide new insights into effective treatment strategies for this challenging condition. Participants receive Tislelizumab, a specially designed immune therapy antibody, combined with chemoradiotherapy in various sequences to convert tumors to a resectable state. The treatments are administered according to assigned groups in a three-arm randomized design. The study carefully monitors treatment responses and side effects to assess the therapies' ability to enable surgery and improve patient outcomes. Throughout the study, patients undergo thorough assessments including physical exams, lab tests, and imaging to evaluate tumor status and organ function. Researchers track the primary outcome of R0 resection rate at 4 months, along with adverse events, morbidity, mortality, and survival at one year. The study also monitors patients' overall health and treatment tolerance to ensure safety and gather comprehensive data on the therapy's effectiveness over time.

Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer